The Role of Laryngopharyngeal Reflux in IPF

Launched by NATIONAL JEWISH HEALTH · Jan 30, 2018

Keywords

ClinConnect Summary

This clinical trial is investigating how a specific measurement called the Supraglottic Index (SGI) can help identify and assess the severity of laryngopharyngeal reflux (LPF) in patients with idiopathic pulmonary fibrosis (IPF). LPF is a condition where stomach contents flow back up into the throat, which can affect breathing and overall health. The goal is to see if the SGI is an easy way to collect information about this condition in people with IPF.

To participate in this study, individuals must be between 40 and 95 years old and have a confirmed diagnosis of IPF. They should also be able to read, speak, and understand English. If they are taking medication for reflux or GERD (gastroesophageal reflux disease), they need to have been on a stable dose for at least four weeks before joining the trial. Participants can expect to undergo assessments that will help researchers understand the link between reflux and IPF, ultimately aiming to improve care for patients facing these challenges. It's important to note that pregnant women cannot participate in this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of IPF
• • Age 40-95
• • Able to read, speak, and understand English
• • If subjects are currently taking medication for reflux or GERD, they much be on a stable does for at least 4 weeks prior to consent.
• Exclusion Criteria:
• • Patients who do not meet all inclusion criteria
• • Pregnant females